Rituximab and chemotherapy for aggressive lymphomas: a significant advance in therapy.
Therapy with rituximab is the most important advance in the treatment of lymphomas since the development of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP). Rituximab has single-agent activity in all types of B-cell lymphomas, including indolent and aggressive disease. For large-cell lymphomas, rituximab plus chemotherapy represents a significant advance over chemotherapy alone without significant added toxicity. Some studies report positive results using the antibody to treat other lymphomas. CHOP plus rituximab has become the standard of care.
Hagemeister
Fredrick B
FB
Department of Lymphoma/Myeloma, Univeristy of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D000069283:Rituximab; D016879:Salvage Therapy / Q000379:methods; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab